Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine

References

• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med.361(23), 2209–2220 (2009).
   PubMed Web of Science ®Google Scholar
• Spearman P, Lally MA, Elizaga M et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J. Infect. Dis.203(8), 1165–1173 (2011).
   PubMed Web of Science ®Google Scholar
• Gilbert P, Wang M, Wrin T et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis.202(4), 595–605 (2010).
   PubMed Web of Science ®Google Scholar
• Yang X, Wyatt R, Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J. Virol.75(3), 1165–1171 (2001).
   PubMed Web of Science ®Google Scholar
• Beddows S, Schuelke N, Kirschner M et al. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol.79(14), 8812–8827 (2005).
   PubMed Web of Science ®Google Scholar
• Beddows S, Franti M, Dey AK et al. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology360(2), 329–340 (2007).
   PubMed Web of Science ®Google Scholar
• Kang YK, Andjelic S, Binley JM et al. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine27(37), 5120–5132 (2009).
   PubMed Web of Science ®Google Scholar
• Barnett SW, Lu S, Srivastava I et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol.75(12), 5526–5540 (2001).
   PubMed Web of Science ®Google Scholar
• Srivastava IK, VanDorsten K, Vojtech L et al. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J. Virol.77(4), 2310–2320 (2003).
   PubMed Web of Science ®Google Scholar
• Buckner C, Gines LG, Saunders CJ et al. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology320(1), 167–180 (2004).
   PubMed Web of Science ®Google Scholar
• Derby NR, Kraft Z, Kan E et al. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J. Virol.80(17), 8745–8762 (2006).
   PubMedGoogle Scholar
• Xu R, Srivastava IK, Kuller L et al. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Virology349(2), 276–289 (2006).
   PubMedGoogle Scholar
• Bogers WM, Davis D, Baak I et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology382(2), 217–225 (2008).
   PubMed Web of Science ®Google Scholar
• Hurwitz JL, Lockey TD, Jones B et al. First Phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants. AIDS22(1), 149–151 (2008).
   PubMedGoogle Scholar
• Burton DR, Desrosiers RC, Doms RW et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol.5(3), 233–236 (2004).
   PubMed Web of Science ®Google Scholar
• Earl PL, Broder CC, Long D et al. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol.68(5), 3015–3026 (1994).
   PubMed Web of Science ®Google Scholar
• Stamatatos L, Lim M, Cheng-Mayer C. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses16(10), 981–994 (2000).
   PubMed Web of Science ®Google Scholar
• Sanders RW, Vesanen M, Schuelke N et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol.76(17), 8875–8889 (2002).
   PubMed Web of Science ®Google Scholar
• Binley JM, Sanders RW, Clas B et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol.74(2), 627–643 (2000).
   PubMed Web of Science ®Google Scholar
• Si Z, Phan N, Kiprilov E et al. Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. AIDS Res. Hum. Retroviruses19(3), 217–226 (2003).
   PubMedGoogle Scholar
• Pancera M, Wyatt R. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology332(1), 145–156 (2005).
   PubMedGoogle Scholar
• Dey AK, David KB, Lu M et al. Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology385(1), 275–281 (2009).
   PubMedGoogle Scholar